Calissa Therapeutics
February 26, 2024
Dermatology
Calissa Therapeutics is a clinical stage dermatology company targeting vascular lesions. Our lead indications are rosacea and port wine birthmark, one of the most common birthmarks. Lead asset CX-001 has been approved ex-US with over 30,000 patients treated. The target product profile includes higher/deeper responses, much less frequent treatment and minimal relapse vs. SOC, based on distinctive MOA that might permanently shut down blood vessels. IND was approved by FDA in 2022 and phase 2 study is ongoing.
)
){kind=logo}
)
){kind=logo}
){kind=logo}